ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 169.8 | 154.5 | 142.4 |
| Other income | 2.2 | 23.9 | -0.3 |
| Total income | 172.0 | 178.4 | 142.1 |
| Profit before exceptional items & tax | 17.1 | 22.2 | 14.6 |
| Exceptional items | 5.2 | 5.9 | -215.9 |
| Profit before tax | 12.0 | 16.4 | 230.5 |
| Net profit | 15.1 | 9.5 | 222.3 |
| Operating margin | 7.0% | 9.2% | 162.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -93.20% |
|---|---|
| Net profit, quarter on quarter | +58.90% |
| Revenue, year on year | +19.20% |
BSE results filing, NSE: INDSWFTLAB. Figures extracted from the filing.
Ind-Swift Laboratories Ltd: key numbers
- Share price
- ₹363.20
- Market cap
- ₹3,158 Cr
- Revenue (annual)
- ₹649.1 Cr
- Net profit (annual)
- ₹43.12 Cr
- P/E (TTM)
- 37.8×Sector 43.8×
- Promoter holding
- 42.93%+0.00% QoQ
- FII holding
- 10.78%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ind-Swift Laboratories Ltd
All →Ind-Swift Laboratories Investor Presentation: Key Takeaways
Q2FY27 operating revenue ₹230.23 Cr, operating EBITDA ₹42.33 Cr (18.02% margin), PAT ₹31.03 Cr (13.21%) after API exit; now net debt-free FDF pure-play.
- Call
- Guides 50% growth
Ind-Swift Laboratories Other Announcement
Ind-Swift Laboratories Limited submitted its quarterly monitoring agency report for the period ended September 30, 2026. The report covers the utilization of Rs. 137.20 Crore raised via warrants.
Ind-Swift Laboratories Convertible Warrants
Ind-Swift Laboratories has fully utilized the Rs. 314.60 Crore proceeds from its preferential issue of convertible warrants. The monitoring agency CARE Ratings confirms no deviations in fund usage.
- Value
- ₹314.6 Cr
Ind-Swift Laboratories Results Update
Ind-Swift Laboratories reported Q2 FY27 revenue up 50% to ₹234.89 crore and PAT up 3.5x to ₹31.03 crore. Operating EBITDA margin rose to 18.02%.
Ind-Swift Laboratories Q2 FY27 Results: Net Profit ₹34.2 Cr, Up 327.5% YoY
Ind-Swift Laboratories Ltd reported revenue from operations of ₹240.5 Cr (+51.6% YoY) and net profit of ₹34.2 Cr (+327.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹34.2 Cr · +327.5% YoY
Ind-Swift Laboratories Board Meeting Date
Ind-Swift Laboratories Ltd. scheduled a board meeting for October 29, 2026, to consider and approve the standalone and consolidated financial results for the quarter and half-year.